{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:03:38Z","timestamp":1793286218922,"version":"4.5.0"},"reference-count":54,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2025,5,24]]},"DOI":"10.1080\/14656566.2025.2499151","type":"journal-article","created":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T19:26:06Z","timestamp":1745781966000},"page":"961-968","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["A review of pharmacokinetic data describing long-acting injectable cabotegravir during pregnancy"],"prefix":"10.1080","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3068-3732","authenticated-orcid":false,"given":"Shawnalyn W.","family":"Sunagawa","sequence":"first","affiliation":[{"name":"University of Nebraska Medical Center","place":["Omaha, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9406-693X","authenticated-orcid":false,"given":"Kimberly K.","family":"Scarsi","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center","place":["Omaha, USA"]},{"name":"University of Nebraska Medical Center","place":["Omaha, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"e_1_3_4_3_1","unstructured":"Geneve: Joint United Nations Programme on HIV\/AIDS. UNAIDS Data 2024 [Internet]. 2024. Available from: https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2024-unaids-global-aids-update_en.pdf"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae331"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26088"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003803"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00051-6"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328359590f"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/09540120701767208"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2013.0005"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411858"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407001"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/23259582211009011"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad390"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30340-4"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32666-0"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00538-4"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101016"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31917-7"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904398"},{"key":"e_1_3_4_21_1","unstructured":"ViiV Healthcare. Cabenuva product monograph [Internet]. 2021 [cited 2023 Aug 14]. Available from: https:\/\/viivhealthcare.com\/content\/dam\/cf-viiv\/viiv-healthcare\/en_GB\/medicines\/CABENUVA-VOCABRIA-PM-26-Mar-2021.pdf"},{"key":"e_1_3_4_22_1","unstructured":"ViiV Healthcare. Apretude product monograph [Internet]. [cited 2024 Feb 22]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215499s000lbl.pdf"},{"key":"e_1_3_4_23_1","volume-title":"Guidelines for HIV post-exposure prophylaxis","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Guidelines for HIV post-exposure prophylaxis. Geneva: WHO; 2024."},{"key":"e_1_3_4_24_1","volume-title":"Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations. Geneva: WHO; 2022."},{"key":"e_1_3_4_25_1","unstructured":"Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States [internet]. Department of health and human services. [cited 2024 Dec 13]. Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/perinatal"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30106-5"},{"key":"e_1_3_4_27_1","unstructured":"International Antiviral Society. IAS Abstract Archive [Internet]. [cited 2025 Jan 28]. Available from: https:\/\/www.abstract-archive.org"},{"key":"e_1_3_4_28_1","unstructured":"Conference on Retroviruses and Opportunistic Infections. CROI Abstract. Available from: https:\/\/www.croiconference.org\/search-abstracts\/"},{"key":"e_1_3_4_29_1","unstructured":"Open Forum Infectious Diseases. OFID Supplements [Internet]. [cited 2025 Jan 28]. Available from: https:\/\/academic.oup.com\/ofid\/supplements"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01475-23"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1310\/hct1405-192"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02057-21"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16006"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100793"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544100-00001"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.116.104174"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498250701744633"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0684-z"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1909512"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002637"},{"key":"e_1_3_4_41_1","unstructured":"IMPAACT Network. IMPAACT 2040 phase I\/II study of the pharmacokinetics and safety of long-acting injectable cabotegravir and rilpivirine in pregnant and postpartum adults with HIV-1 [Internet]. 2024 [cited 2025 Jan 11]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06336434"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13439"},{"key":"e_1_3_4_43_1","unstructured":"Delany-Moretlwe S Hughes JP Guo X et al. Evaluation of CAB-LA safety and PK in pregnant women in the blinded phase of HPTN 084."},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae242"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26401\/full|10.1002\/jia2.26401"},{"key":"e_1_3_4_46_1","unstructured":"Marzinke M Voldal E Hanscom B et al. Evaluation of long-acting cabotegravir (CAB-LA) pharmacokinetics during pregnancy: a sub-study analysis of the HPTN 084 open label extension study. Munich: AIDS; 2024. Available from: https:\/\/www.abstract-archive.org\/"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00781-23"},{"key":"e_1_3_4_48_1","unstructured":"Panel on Antiretroviral Guidelines for Adults N. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV How to cite the adult and adolescent antiretroviral guidelines: panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of health and human services [Internet]. Available from: https:\/\/clinicalinfo.hiv.gov\/"},{"key":"e_1_3_4_49_1","unstructured":"Centers for Disease Control and Prevention: US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2021 update [Internet]. 2021. Available from: https:\/\/www.cdc.gov\/hiv\/pdf\/risk\/prep\/cdc-hiv-prep-guidelines-2021.pdf"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu709"},{"issue":"2","key":"e_1_3_4_51_1","first-page":"39","article-title":"FDA approval for use of medications in pregnancy: an uphill battle","volume":"4","author":"Norwitz ER","year":"2011","unstructured":"Norwitz ER, Greenberg JA. FDA approval for use of medications in pregnancy: an uphill battle. Rev Obstet Gynecol. 2011;4(2):39\u201341.","journal-title":"Rev Obstet Gynecol"},{"key":"e_1_3_4_52_1","volume-title":"Advancing clinical research with pregnant and lactating populations: overcoming real and perceived liability risks","author":"March A","year":"2024","unstructured":"March A, Helman ARiley MFeditors. Advancing clinical research with pregnant and lactating populations: overcoming real and perceived liability risks. Washington (DC): National Academies Press (US); 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK603025\/"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3181d53843"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13218"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-022-03721-6"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2016.1235972"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2025.2499151","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T03:03:15Z","timestamp":1748833395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2025.2499151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,5,24]]}},"alternative-id":["10.1080\/14656566.2025.2499151"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2025.2499151","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-02-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}